With thousands of UPLC systems and UPLC columns delivered worldwide, see why the world's top-branded companies and institutions have standardized on ACQUITY UPLC: the fastest-growing new LC platform in the market for five years running.
"We're always looking to improve quality and efficiency in our group, and UPLC® answered this for us. Waters has a reputation for being the gold standard of high-pressure chromatography." - Powell K., Enthalpy Analytical, Inc.
To satisfy their customers' fundamental need for faster, high-quality laboratory results, one analytical services organization selected the Waters ACQUITY UPLC® System - it also matched the company's overall streamlining efforts.
As many pharmaceutical companies strive to shorten drug development time by using contract laboratories, these organizations are increasingly relied upon for not only their analytical expertise, but also for offering far greater efficiencies at a lower cost. With a robust laboratory workflow, it's easy to stand out from competitors.
Eliminate analytical work backlogs and slow turnaround times
Increase laboratory flexibility, quality, and efficiency
Assure capacity ahead of increasing demand, and can commit to meet deadlines consistently
CONTACT: www.waters.com
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.